Answers are grounded in this paper and cite their sources.
INTRODUCTION: Drug-drug interactions (DDIs) are a preventable cause of adverse drug events (ADEs), yet conventional interaction-checking tools are hampered by incomplete knowledge, poor concordance, and clinically unusable alert burdens. Artificial intelligence (AI) is increasingly utilized to strengthen multiple stages of the DDI pathway. AREAS COVERED: This narrative review synthesizes literature identified through searches conducted between 15 July and 20 October 2026. It examines how machine learning (ML) predicts novel drug interactions from molecular structure and knowledge graphs; how natural language processing (NLP) and large language models (LLMs) identify and extract interactions from the literature, drug labels, and pharmacovigilance data; and how AI can make clinical decision support context-aware and support medication review. It also integrates mechanistic physiologically based pharmacokinetic (PBPK) modeling and individualized patient-level risk prediction. EXPERT OPINION: Prediction models achieve impressive benchmark accuracy but frequently underperform in realistic, cold-start settings; LLMs detect interactions with high sensitivity but show poor severity calibration and persistent hallucination. The near-term value of AI lies less in autonomous prediction than in curating knowledge, personalizing alerts, and augmenting clinician judgment. Rigorous external validation, interpretability, and regulatory clarity are prerequisites for clinical adoption.
No takes yet. Share an insight, caveat, or question.
Yiu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: